基于结构和药效团特征的人类腺苷受体拮抗剂选择性比较

腺苷受体是重要的治疗靶标,选择性腺苷受体拮抗剂具有广泛的临床应用前景.本文通过同源模建构建了腺苷A₁、A_2B和A₃受体的结构,采用LigandScout 3.12软件分别构建了腺苷受体四种亚型的拮抗剂药效团模型.然后利用Schrödinger程序中的Induced Fit Docking模块完成受体-拮抗剂结合模式的预测,并与药效团结果进行比对.结果发现,由于结合口袋部位的残基在家族间高度保守,模建得到的各个亚型受体的初始结构活性口袋部位极为相似,无法用于亚型选择性拮抗剂的识别.而腺苷受体四种亚型拮抗剂药效团的药效特征与空间排布都不同,并与以前突变实验信息相吻合.研究结果说明,结合口袋部位的优化是模建中的关键步骤,基于配体的药效团模型所包含的一系列药效特征元素如氢键受体、氢键供体、疏水基团、芳环中心,可以很好地表征受体结合部位氢键、疏水空腔的位置及其方向.本文研究结果可以为进一步的优化同源模建结果,寻找新型的人类腺苷受体选择性拮抗剂提供理论依据.     

3C-like蛋白酶抑制剂的构效关系、分子对接和分子动力学

3C-like蛋白酶是中东呼吸综合征冠状病毒（MERS-CoV）等其它冠状病毒的繁殖过程中极为重要的蛋白酶。它已成为人类在抗冠状病毒领域中的研究热点。本文基于计算生物学方法对与MERS-CoV同属的蝙蝠冠状病毒HKU4（HKU4-CoV）的43个肽类3C-like蛋白酶抑制剂分子,建立三维定量构效关系（3D-QSAR）模型。在基于配体叠合的基础上,发现比较分子相似性指数分析法（CoMSIA）中的四个场组合（位阻场、静电场、氢键供体场与氢键受体场）为最优的模型（Q²=0.522,R_ncv²=0.996,R_pre²=0.904;Q²：交叉验证相关系数,R_ncv²：非交叉验证相关系数,R_pre²：验证集分子的预测值相关系数）,并借助该模型通过分子对接（docking）与分子动力学（MD）方法阐明了配受体结合作用。实验结果表明：（1）基于最优的CoMSIA模型基础上的三维等势图形象地说明了分子基团的位阻作用、静电作用、氢键供体与氢键受体作用对分子生物活性的影响;（2）分子对接研究结果显示了疏水性以及结晶水、氨基酸His166和Glu169在配体和受体结合过程中产生重要作用;（3）分子动力学模拟进一步验证了分子对接模型的可靠性,并发现了两个新的关键氨基酸Ser24与Gln192,它们与配体产生了两个较强的氢键。此外,根据这些结果,一些新的具有潜在抑制活性的肽类化合物作为3C-like蛋白酶抑制剂被获得。以上结果能够帮助深入了解3C-like蛋白酶与肽类抑制剂的作用机理,并且能够为今后的抗MERS-CoV药物设计提供有价值的参考。     

新烟碱类化合物药效构象的分子对接研究

从烟碱型乙酰胆碱受体(nACHR)-烟碱(nicotine)复合体晶体模型出发, 采用SYBYL 6.92软件包中FlexX分子对接模块对新烟碱类化合物的3种已上市化合物吡虫啉、噻虫啉、烯啶虫胺和3种吡虫啉的结构衍生物同受体蛋白作用的精确模型进行了研究. 通过全局搜索方法构建配体的构象库进行对接, 依据构象间RMS值对结果进行分类结合CScore打分函数数据对对接结果进行筛选, 最终给出合理的新烟碱类化合物-烟碱型乙酰胆碱受体的药效作用构象模型: 配体吡啶环上氮原子通过水分子同受体Leu102, Met114形成氢键并且咪唑环或噻唑环上亲水侧链同受体CYS187或SER186形成氢键, 疏水侧链同疏水部位A (TYR164, TRP53, TYR89以及TYR185残基), 或疏水部位B (TYR132, CYS187和CYS188)相互作用. 此模型同早先有关文献报道的试验结果部分吻合, 充分表明了其合理性. 同时依据本构象模型, 在新烟碱类化合物结构方面提出了一些改良建议并为研究其高选择性指出方向.     

基于昆虫气味结合蛋白的新型酰基哌啶类化合物的构效关系

利用Sybyl7.3软件对29个具有驱避活性的新型酰基哌啶类化合物与气味结合蛋白AgamOBP1的结合模式进行研究,发现二者之间的结合以疏水作用和水桥作用为主. 其中酰基哌啶类化合物末端的疏水片段可与AgamOBP1结合腔内狭长的疏水通道产生相互作用. 同时,其关键药效基团——酰基氧可通过HOH153与AgamOBP1中的关键残基Trp114和Gly92或Cys95形成多重氢键作用. 利用比较分子力场分析法（CoMFA）和比较分子相似性指数分析法（CoMSIA）构建了新型酰基哌啶类化合物的三维定量构效关系（3D-QSAR）模型,其交叉验证系数r_cv²分别为0.650和0.587. 研究表明,在CoMSIA模型中,疏水场、静电场和立体场组合所得的三维构效关系模型最佳,其中尤以疏水场对这类酰基哌啶类化合物的驱避活性最为重要. 基于AgamOBP1靶标结合口袋特征和酰基哌啶类化合物的3D-QSAR模型得出具有驱避活性的酰基哌啶类化合物的构效关系如下：在酰基C上引入一定碳链长度的疏水基团可使化合物表现出驱避活性,其中又以含9~10个C的化合物的驱避活性最佳,这与AgamOBP1结合口袋的疏水性质密不可分;当酰基端碳链长度一定时,在哌啶环上不宜引入立体效应过大的取代基,这是由AgamOBP1结合口袋的大小决定的;与哌啶N相连的酰基作为氢键受体基团,对于化合物识别与结合AgamOBP1蛋白至关重要.     

二氢嘧啶并[4,5-d]嘧啶类衍生物作为集落刺激因子-1受体激酶抑制剂的分子对接和定量构效关系研究

集落刺激因子-1受体激酶(CSF-1R)属于Ⅲ型受体酪氨酸激酶家族成员,其在调控单核巨噬细胞系中发挥重要作用。CSF-1R及其配体异常表达与肿瘤发展过程密切相关。因此,CSF-1R信号传导可成为抗肿瘤治疗的有吸引力的靶标。本文用比较分子场分析法(Co MFA)和比较分子相似性指数分析法(Co MSIA)研究了54个二氢嘧啶并[4,5-d]嘧啶类CSF-1R激酶抑制剂的三维定量构效关系(3D-QSAR)。基于配体叠合,Co MFA和Co MSIA模型的交叉验证系数(q~2)分别为0. 725和0. 636,拟合验证系数(r~2)分别为0. 960和0. 958,结果表明这两种模型均具有较好的预测能力。所建模型的等势图能直观反映分子不同取代基对活性的影响,其中立体场和疏水场对活性的贡献较大。通过分子对接研究显示,氨基酸残基Cys666、Asp796在配体和受体结合过程中产生作用,分子对接的结合模式与3D-QSAR得到的结果一致。这些信息为进一步优化CSF-1R激酶抑制剂提供了理论基础。     

配体调控钯催化乙烯基环状碳酰胺和异氰酸酯的差异性转化（英文）

用配体调控策略,通过钯催化发展了乙烯基环状碳酰胺和异氰酸酯之间的两类差异性转化,选择性地合成了多取代的共轭二烯脲类化合物和四氢嘧啶酮衍生物.当反应以Pd₂(dba)₃?CHCl₃ (dba:dibenzylideneacetone)为催化剂前体、以单齿配位的N,N-二甲基亚磷酰胺(Mono Phos)为配体时,可以高选择性地得到一系列线性的共轭二烯脲类衍生物;将配体改为双齿配位的1,3-双(二苯基膦)丙烷(DPPP)时,利用相同的原料则能够合成一系列环状的四氢嘧啶酮类化合物.这一研究通过简便的配体调控策略,为含氮化合物的多样性合成提供了新方法.     

雌激素β受体喹啉类配体的分子对接及3D-QSAR研究

对33个喹啉衍生物的雌激素β受体活性进行了分子对接以及比较分子力场分析(CoMFA)和比较分子相似性指数分析(CoMSIA). 对接结果显示氢键和疏水作用是配体与受体结合的主要因素,同时结果亦显示对接结合能与观测值pIC50具有极显著的线性相关性. 根据对接后各优势构象将33个样本进行叠合并进行CoMFA与CoMSIA研究,均得到了较优的结果,其中以选用立体场、静电场和疏水场建立的CoMSIA模型结果最优,其主成分数,r2,q2（LOO）和r2pred分别为2, 0.894, 0.708和0.802. 构效关系模型分析显示基团的空间位阻、电性及疏水作用是影响活性的主要因素     

DCN1-UBE2M相互作用抑制剂的3D-QSAR、分子对接和分子动力学研究

类泛素化是一种蛋白质翻译后修饰,其异常会导致神经退行性疾病和多种肿瘤的发生,因此它被视为有希望的抗肿瘤靶标。研究表明,抑制DCN1-UBE2M相互作用可选择性阻遏类泛素化。本文基于哌啶基脲类DCN1-UBE2M相互作用抑制剂进行3D-QSAR、分子对接和分子动力学模拟研究。利用3D-QSAR中的CoMFA和CoMSIA方法构建了相关模型,其交叉验证系数q~2分别为0.686、0.682,拟合验证系数r~2分别为0.966、0.931,表明模型是可靠的且预测能力较好。接着运用分子对接分析哌啶基脲类化合物与DCN1的相互作用,结果表明,它们主要通过氢键和疏水作用与靶蛋白结合。通过分子动力学模拟研究进一步了解结合模型和验证对接结果。本文所得的研究结果可为今后此类化合物的结构优化提供有效信息。     

5-甲氧基色胺苯基哌嗪衍生物的合成及其α1-受体拮抗活性

α1-受体拮抗剂是目前临床治疗良性前列腺增生的一类有效药物,现有的α1-受体拮抗剂主要有喹唑啉类、哌啶类、苯基哌嗪类和苯乙胺类.综合已有的几类α1-受体拮抗剂的构效关系,我们发现多数苯基哌嗪类药物均具有较好的尿道组织选择性和α1-受体亚型选择性.     

螺环吲哚类MDM2抑制剂的分子对接、定量构效关系和分子动力学模拟

采用分子对接、三维定量构效关系(3D-QSAR)和分子动力学方法研究了21个螺环吲哚类化合物与MDM2蛋白的相互作用, 并建立了相关预测模型. 比较分子场分析法(CoMFA)和比较分子相似性指数分析法(CoMSIA)模型的交互验证相关系数q²分别为0.573 和0.651, 非交互验证相关系数r²分别为0.948和0.980. 分子对接得到的结合模式与分子动力学模拟得到的结果一致, 结合模式表明该类螺环吲哚化合物主要通过疏水相互作用和氢键与MDM2结合. 基于上述相互作用模型设计并合成了6个新结构螺环吲哚化合物, 并在MDM2高表达的前列腺癌LNCaP细胞株上测定其活性, 结果表明化合物5, 6的半数抑制浓度均低于1μg·mL^-1, 可作为新的抗肿瘤药物先导化合物进一步深入研究. 本研究对以MDM2为靶点的新结构螺环吲哚类抑制剂的开发提供了理论和实验依据.     

Synthesis and biological evaluation of novel 9-heteroaryl substituted 7-chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptor antagonists

In this paper, we report a study on some new 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylate derivatives (TQXs), bearing a nitrogen-containing heterocycle at position-9, and designed as (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptor antagonists. These compounds ensue from the structural modification of previously reported 8-heteroaryl-TQXs which were endowed with high affinity and selectivity for the AMPA receptor. All the newly synthesized compounds were biologically evaluated for their binding at the AMPA receptor. Gly/N-methyl-D-aspartic acid (NMDA) and kainic acid (KA) high-affinity binding assays were performed to assess the selectivity of the reported derivatives toward the AMPA receptor. This study produced some new TQXs which are less potent than the reference compounds, and endowed with a mixed AMPA and Gly/NMDA receptor binding affinity. To rationalize the experimental findings, a molecular modeling study was performed by docking some TQX derivatives to the AMPA receptor model.     

芳香噻嗪类衍生物作为选择性醛糖还原酶抑制剂的分子对接和基于受体的三维定量构效关系研究

芳香噻嗪类衍生物被证明是一类选择性较好的高活性醛糖还原酶抑制剂(ARIs).本文对44个芳香噻嗪类化合物进行了分子对接(docking)和三维定量构效关系(3D-QSAR)研究,并探索了此类化合物与醛糖还原酶(ALr²)的作用机理.醛糖还原酶与醛还原酶(ALR1)活性位点的叠加结果显示, ALr²中残基Leu 300和Cys298的存在是化合物1m具有高选择性的原因.分别建立了比较分子场分析方法(CoMFA, q² = 0.649, r² =0.934; q²:交叉验证相关系数, r²:非交叉验证相关系数)和比较分子相似性指数分析方法(CoMSIA, q² = 0.746, r² = 0.971)模型,并对影响此类化合物生物活性的结构进行了鉴定.结果显示,两个模型均具有较高预测能力,并通过测试集中的7个化合物进行了验证,其中CoMFA模型和CoMSIA模型的预测相关系数(r_Pred²)分别为0.748和0.828. 3D-QSAR模型中的三维等值线图表明,在化合物1m的苄基环上C3和C4位置以及苯并噻嗪母核上C5和C7位置进行改进可能对生物活性的提高有利,此预测与我们前期报道的苯并噻嗪母核C7位改进结果一致.本文所建3D-QSAR模型能够在理性设计具有更高生物活性的新型ARIs中发挥重要作用.     

Cε3-Cε4蛋白寡核苷酸适配子结合位点的预测与筛选

采用NPDock程序对Cε3-Cε4蛋白与其核酸适配子A1的结合位点进行了预测与筛选, 筛选出A1与Cε3-Cε4蛋白结合的关键位点. 同时, 根据蛋白与DNA片段复合物结合界面中氨基酸残基和碱基统计分析发现, 结合界面氨基酸富集碱基G能力最强, 富集碱基T和C能力次之. 本文建立了以NPDock程序虚拟对接为基础的高效适配子优化方法, 为相关研究提供了实验参考.     

Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-beta receptor (PDGFbeta R) inhibitors, derived from molecular modeling

We previously reported a quinoxalin-2-one compound (Compound 1) that had inhibitory activity equivalent to existing platelet-derived growth factor-beta receptor (PDGFbeta R) inhibitors. Lead optimization of Compound 1 to increase its activity and selectivity, using structural information regarding PDGFbeta R-ligand interactions, is urgently needed. Here we present models of the PDGFbeta R kinase domain complexed with quinoxalin-2-one derivatives. The models were constructed using comparative modeling, molecular dynamics (MD) and ligand docking. In particular, conformations derived from MD, and ligand binding site information presented by alpha-spheres in the pre-docking processing, allowed us to identify optimal protein structures for docking of target ligands. By carrying out molecular modeling and MD of PDGFbeta R in its inactive state, we obtained two structural models having good Compound 1 binding potentials. In order to distinguish the optimal candidate, we evaluated the structural activity relationships (SAR) between the ligand-binding free energies and inhibitory activity values (IC50 values) for available quinoxalin-2-one derivatives. Consequently, a final model with a high SAR was identified. This model included a molecular interaction between the hydrophobic pocket behind the ATP binding site and the substitution region of the quinoxalin-2-one derivatives. These findings should prove useful in lead optimization of quinoxalin-2-one derivatives as PDGFb R inhibitors.     

辛味中药与嗅觉受体相互作用的分子模拟

采用分子模拟的方法, 在Schrdinger软件平台上, 用同源模建的方法构建了嗅觉受体OR1D2, OR7D4和OR51E1的三维结构模型. 运用分子动力学模块Desmond将与激动剂以及抑制剂分别对接的嗅觉受体复合物置于磷脂双膜中进行模拟. 最后将辛味中药的小分子分别对接到嗅觉受体中, 并与苦味中药的对接结果相对照, 依据实验结果, 讨论辛味中药发挥作用的分子机制. 该研究着重于同源模建、分子动力学和分子对接技术的综合应用, 探讨辛味中药化学成分与嗅觉受体的相互作用及其分子机理, 为从分子层面揭示辛味中药的药效物质基础提供帮助, 也为中药药性的研究提供了新的思路和方法.     

On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches

Human chemokine receptor CXCR3 (hCXCR3) antagonists have potential therapeutic applications as antivirus, antitumor, and anti-inflammatory agents. A novel virtual screening protocol, which combines pharmacophore-based and structure-based approaches, was proposed. A three-dimensional QSAR pharmacophore model and a structure-based docking model were built to virtually screen for hCXCR3 antagonists. The hCXCR3 antagonist binding site was constructed by homology modeling and molecular dynamics (MD) simulation. By combining the structure-based and ligand-based screenings results, 95% of the compounds satisfied either pharmacophore or docking score criteria and would be chosen as hits if the union of the two searches was taken. The false negative rates were 15% for the pharmacophore model, 14% for the homology model, and 5% for the combined model. Therefore, the consistency of the pharmacophore model and the structural binding model is 219/273 = 80%. The hit rate for the virtual screening protocol is 273/286 = 95%. This work demonstrated that the quality of both the pharmacophore model and homology model can be measured by the consistency of the two models, and the false negatives in virtual screening can be reduced by combining two virtual screening approaches.     

Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit

The stereochemistry of the heterocyclic alcohols (R₁-OH~R₄-OH,see Fig.1) containing piperidine unit has been studied on the basis of the calculations of molecular mechanics and quantum chemistry. The calculations of alcohols (R₁-OH~R₄-OH) and their carboxylate derivatives were carried out, and the results of these calculations were listed in Tab.1 and Tab.2. It was showed that there existed the non-classical orbital super-conjugated interactions between the nitrogen atom and oxygen atom which caused the conformations to be more stable when the hydroxylic group lay at axial than at equatorial with respect to the piperidine ring in compounds (R₁-OH) and (R₃-OH). If the axial hydrogen atoms at C₂ and C₆ positions in the piperidine ring were substituted, or the molecular existed in the polar solutions, this non-classical orbital super-conjugated interactions would be much weak even diminished. In this case,the conformations were more stable when the hydroxylic group at equatorial than at axial in these compounds. These consistented with the experimental results.     

Synthesis and biological evaluation of novel 1, 2, 3-benzotriazin-4-one derivatives as leukotriene A4 hydrolase aminopeptidase inhibitors

A series of novel 1,2,3-benzotriazin-4-one derivatives were designed,synthesized and their inhibitory activities against leulcotriene A_4 hydrolase aminopeptidase in vitro were evaluated.Many compounds showed moderate to good activities at the concentration of 10 μmol/L.Among them,compound Ⅳ-16 exhibited the highest inhibitory activity up to 80.6% with an IC_(50) of 1.30 ± 0.20 μmol/L The compound Ⅳ-16 was also tested the proliferation inhibitory activities in THP1 human AML cell line and its binding model with LTA_4H enzyme by molecular docking was studied.It indicated that 1,2,3-benzotriazin-4-one was a promising scaffold for further study.The relationship between structure and inhibitory activity was also preliminarily discussed.     

Interaction between human telomere and a carbazole derivative: a molecular dynamics simulation of a quadruplex stabilizer and telomerase inhibitor

The mechanism of inhibition of telomerase by drugs is a key factor in an understanding of guanine-quadruplex complex stabilization during human cancer. This study describes a simulated annealing docking and molecular dynamics simulation to investigate a synthesized potent inhibitor, 3,6-bis(1-methyl-4-vinylpyridinium iodine) carbazole (BMVC), which stabilizes the quadruplex structure of the human telomeric DNA sequence d[AG3(T(2)AG(3))3] and inhibits telomerase activity. The compound was predicted to selectively interact with the quadruplex structure. During our simulation, the binding affinities were calculated and used to predict the best drug-binding sites as well as enhanced selectivity compared with other compounds. Our studies suggest that the simulation results quite coincide with the experimental results. In addition, molecular modeling shows that a 2:1 binding model involving the external binding of BMVC to both ends of the G-quartet of d[AG(3)(T(2)AG)3))3] is the most stable binding mode and this agrees with the absorbance titration results that show two binding sites. Of particular interest is that one pyridinium ring and carbazole moiety of the BMVC can stack well at the end of G-quartet. This implies that BMVC is a good human quadruplex stabilizer and also a good telomerase inhibitor.